|

Zongertinib Clinical Trials

4 actively recruiting trials across 3 locations

▲ +1 trial since June 2026

Also known as: BI 1810631, Hernexeos®, Hernexeos®

Pipeline

Phase 2: 2Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Boehringer Ingelheim4

Indications

  • Cancer4
  • Lung Cancer2
  • Lung Cancer, Non-squamous, Non-small Cell1
  • Metastatic Gastric Adenocarcinoma1
  • Gastroesophageal Junction Adenocarcinoma1

Other1 trial

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
Phase 2

Anchorage, Alaska1 trial

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

Alaska Oncology and Hematology, LLC

Phase 2

Cerritos, California1 trial

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

The Oncology Institute of Hope and Innovation

Phase 1/2

Fresno, California1 trial

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

ClinRé 001-022 (Premier Cancer Care and Infusion Center)

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.